Lawsuit filed for Investors who lost money with shares of Altimmune, Inc. (NASDAQ: ALT)

An investor, who purchased shares of Altimmune, Inc. (NASDAQ: ALT), filed a lawsuit over alleged violations of Federal Securities Laws by Altimmune, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and for certain investors are short and strict deadlines running. Deadline: October 6, 2025. NASDAQ: ALT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Gaithersburg, MD based Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

On June 26, 2025, Altimmune, Inc. (NASDAQ: ALT) published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While defendants had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, defendants answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. Following this news, the price of Altimmune's common stock declined dramatically.

Shares of Altimmune, Inc. (NASDAQ: ALT) declined from $14.84 per share on February 28, 2024, to as low as $2.90 per share on June 26, 2024.

The plaintiff claims that between August 10, 2023 and June 25, 2025, the The Altimmune class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information pertaining to the results of Altimmune's IMPACT Phase 2b metabolic associated steatohepatitis ("MASH") trial; (ii) Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint; and (iii) Altimmune concealed higher responses in the placebo group, which defendants knew or should have known would negatively impact the IMPACT Phase 2b MASH trial's topline results.
The Altimmune class action lawsuit further alleges that on June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH and disclosed that "[a]lthough we saw positive trends in fibrosis improvement, statistical significant was not achieved on this endpoint." On this news, the price of Altimmune stock fell more than 53%, according to the complaint.

Those who purchased shares of Altimmune, Inc. (NASDAQ: ALT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.